Which is better, AUPH or GMAB?

On the Buffett-Fit framework, Genmab A/S (GMAB) currently grades higher than AUPH — 65/100 (C grade) vs 56/100 (C). That said, "better" depends on which framework you trust — AUPH wins on Philip Fisher and Peter Lynch; GMAB wins on Warren Buffett, Benjamin Graham, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy AUPH or GMAB?

This page is an educational comparison, not investment advice. Both AUPH and GMAB are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is AUPH better than GMAB for value investing?

On the Buffett-style value-investing framework, GMAB currently grades higher — 65/100 vs 56/100, a 9-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between AUPH and GMAB on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). AUPH currently scores 56/100 (C grade); GMAB scores 65/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, AUPH or GMAB?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. AUPH and GMAB are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, AUPH or GMAB?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are AUPH and GMAB both Healthcare stocks?

Yes — both Aurinia Pharmaceuticals Inc. (AUPH) and Genmab A/S (GMAB) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this AUPH vs GMAB comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Aurinia Pharmaceuticals

Genmab A/S

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

AUPH

Market cap

$1.96B

Sector

Healthcare

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

Overall winner

Genmab A/S GMAB

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	AUPH	GMAB	Winner
Warren Buffett	56C	65C	GMAB
Benjamin Graham	54D	64C	GMAB
Philip Fisher	59C	48D	AUPH
Peter Lynch	81A	25F	AUPH
Joel Greenblatt	63C	76B	GMAB
Charlie Munger	49D	68C	GMAB
Terry Smith	48D	71C	GMAB

Side-by-side metrics

Metric	AUPH	GMAB
Market cap	$1.96B	$16.5B
P/E (TTM)	6.9x	6.2x
EV/EBIT	19.4x	12.0x
ROIC (TTM)	18.99%	43.78%
Gross margin	89.74%	93.88%
Net margin	99.97%	18.23%
Revenue CAGR 5y	57.84%	-18.45%
EPS CAGR 5y	-	-23.48%
Debt / Equity	0.1x	0.1x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

AUPH leads on

Revenue CAGR 5y57.84%vs -18.45%+132%
Net margin99.97%vs 18.23%+82%

GMAB leads on

Market cap$16.5Bvs $1.96B+88%
ROIC (TTM)43.78%vs 18.99%+57%
Debt / Equity0.1xvs 0.1x+39%
EV/EBIT12.0xvs 19.4x+38%

More like AUPH

AUPH vs IDXX AUPH vs 7741.T AUPH vs SUNPHARMA.NS AUPH vs LMAT AUPH vs HALO AUPH vs MTD

More like GMAB

GMAB vs IDXX GMAB vs 7741.T GMAB vs SUNPHARMA.NS GMAB vs LMAT GMAB vs HALO GMAB vs MTD

Read the full Buffett-Brain analysis for AUPH Read the full Buffett-Brain analysis for GMAB

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Stock comparison

Aurinia Pharmaceuticals

Genmab A/S

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

AUPH

Aurinia Pharmaceuticals

Market cap

$1.96B

Sector

Healthcare

GMAB

Genmab A/S

Market cap

$16.5B

Sector

Healthcare

Overall winner

Genmab A/S GMAB

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	AUPH	GMAB	Winner
Warren Buffett	56C	65C	GMAB
Benjamin Graham	54D	64C	GMAB
Philip Fisher	59C	48D	AUPH
Peter Lynch	81A	25F	AUPH
Joel Greenblatt	63C	76B	GMAB
Charlie Munger	49D	68C	GMAB
Terry Smith	48D	71C	GMAB

Side-by-side metrics

Metric	AUPH	GMAB
Market cap	$1.96B	$16.5B
P/E (TTM)	6.9x	6.2x
EV/EBIT	19.4x	12.0x
ROIC (TTM)	18.99%	43.78%
Gross margin	89.74%	93.88%
Net margin	99.97%	18.23%
Revenue CAGR 5y	57.84%	-18.45%
EPS CAGR 5y	-	-23.48%
Debt / Equity	0.1x	0.1x
Dividend yield	0.0%	0.0%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

AUPH leads on

Revenue CAGR 5y57.84%vs -18.45%+132%
Net margin99.97%vs 18.23%+82%

GMAB leads on

Market cap$16.5Bvs $1.96B+88%
ROIC (TTM)43.78%vs 18.99%+57%
Debt / Equity0.1xvs 0.1x+39%
EV/EBIT12.0xvs 19.4x+38%

More like AUPH

AUPH vs IDXX AUPH vs 7741.T AUPH vs SUNPHARMA.NS AUPH vs LMAT AUPH vs HALO AUPH vs MTD

More like GMAB

GMAB vs IDXX GMAB vs 7741.T GMAB vs SUNPHARMA.NS GMAB vs LMAT GMAB vs HALO GMAB vs MTD

Read the full Buffett-Brain analysis for AUPH Read the full Buffett-Brain analysis for GMAB

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.